Back
Adaptimmune Therapeutics PLC 10K Form
Sell
11
ADAP
Adaptimmune Therapeutics PLC
Last Price:
$0.20
Seasonality Move:
20.42%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2023-11-08 | 10Q | ADAP/Adaptimmune Therapeutics PLC Quarterly |
| 2023-08-09 | 10Q | ADAP/Adaptimmune Therapeutics PLC Quarterly |
| 2023-05-12 | 10Q | ADAP/Adaptimmune Therapeutics PLC Quarterly |
| 2022-11-08 | 10Q | ADAP/Adaptimmune Therapeutics PLC Quarterly |
| 2022-08-04 | 10Q | ADAP/Adaptimmune Therapeutics PLC Quarterly |
| 2022-05-09 | 10Q | ADAP/Adaptimmune Therapeutics PLC Quarterly |
Receive ADAP News And Ratings
See the #1 stock for the next 7 days that we like better than ADAP
ADAP Financial Statistics
Sales & Book Value
| Annual Sales: | $178M |
|---|---|
| Cash Flow: | $-35.4M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $0.05 |
| Price / Book: | 4.47 |
Profitability
| EPS (TTM): | -0.31350 |
|---|---|
| Net Income (TTM): | $-70.8M |
| Gross Margin: | $178M |
| Return on Equity: | -140.5% |
| Return on Assets: | -24.83% |
Adaptimmune Therapeutics PLC Earnings Forecast
Key Adaptimmune Therapeutics PLC Financial Ratios
-
The Gross Profit Margin over the past 9 years for ADAP is 99.96%.
-
The Selling, General & Administrative Expenses for ADAP have been equal to 45.67% of Gross Profit Margin.
-
The Research & Development expenses have been 83.73% of Revenue.
-
The Net Earning history of ADAP is -39.78% of Total Revenues.
-
Per Share Earnings over the last 12 years have been positive in 4 years.
Adaptimmune Therapeutics PLC Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | ADAP |
| CUSIP: | 00653A |
| Website: | adaptimmune.com |
Debt
| Debt-to-Equity Ratio: | 4.24 |
|---|---|
| Current Ratio: | 2.92 |
| Quick Ratio: | 2.6 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
ADAP Technical Analysis vs Fundamental Analysis
Sell
11
Adaptimmune Therapeutics PLC (ADAP)
is a Sell
Is Adaptimmune Therapeutics PLC a Buy or a Sell?
-
Adaptimmune Therapeutics PLC stock is rated a SellThe current Adaptimmune Therapeutics PLC [ADAP] share price is $0.21. The Score for ADAP is 11, which is 78% below its historic median score of 50, and infers higher risk than normal.